{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=25%25+Mannitol", "query": { "intervention": "25% Mannitol" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=25%25+Mannitol&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-21T15:46:03.053Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00042367", "title": "Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain Tumors" ], "interventions": [ { "name": "Induction therapy (Regimen 1, Course 1, Cycle A1", "type": "DRUG" }, { "name": "Regimen 1, Course 1, Cycle A2 (Days 22 - 42)", "type": "DRUG" }, { "name": "Cycle B", "type": "DRUG" }, { "name": "Regimen 1, Course 2", "type": "DRUG" }, { "name": "Intrathecal Mafosfamide", "type": "DRUG" }, { "name": "Regimen 1 Course 2, IT mafosfamide", "type": "DRUG" }, { "name": "Regimen 2, Course 1", "type": "DRUG" }, { "name": "Regimen 2, Course, 1, Cycle C1", "type": "DRUG" }, { "name": "Regimen 2, Course 2", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "36 Months", "sex": "ALL", "summary": "Up to 36 Months" }, "enrollment_count": 119, "start_date": "2000-04-04", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-09-21T15:46:03.053Z", "location_count": 3, "location_summary": "Durham, North Carolina • Memphis, Tennessee • Houston, Texas", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00042367" }, { "nct_id": "NCT00787761", "title": "Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Disorders", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "nonmyeloablative allogeneic HSCT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 24, "start_date": "2007-04", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2012-10-01", "last_synced_at": "2026-09-21T15:46:03.053Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787761" }, { "nct_id": "NCT02938520", "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir (CAB) tablet", "type": "DRUG" }, { "name": "Rilpivirine (RPV) tablet", "type": "DRUG" }, { "name": "Cabotegravir - Injectable Suspension (CAB LA)", "type": "DRUG" }, { "name": "Rilpivirine - Injectable Suspension (RPV LA)", "type": "DRUG" }, { "name": "ABC/DTG/3TC STR - Tablet", "type": "DRUG" }, { "name": "DTG Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 631, "start_date": "2016-10-27", "completion_date": "2029-12-31", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-21T15:46:03.053Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02938520" }, { "nct_id": "NCT00238173", "title": "Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bone Marrow Suppression", "Brain and Central Nervous System Tumors", "Drug/Agent Toxicity by Tissue/Organ", "Long-term Effects Secondary to Cancer Therapy in Children" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "acetylcysteine", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "mannitol", "type": "DRUG" }, { "name": "sodium thiosulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 2, "start_date": "2004-12", "completion_date": "2006-02-17", "has_results": false, "last_update_posted_date": "2017-04-21", "last_synced_at": "2026-09-21T15:46:03.053Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00238173" }, { "nct_id": "NCT03786796", "title": "Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Kidney Cancer", "Renal Carcinoma", "Kidney Cancer Metastatic" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 20, "start_date": "2019-06-03", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-09-21T15:46:03.053Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03786796" }, { "nct_id": "NCT00832637", "title": "Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Cholangiocellular Carcinoma", "Cholangiocarcinoma of the Extrahepatic Bile Duct", "Bile Duct Cancer", "Periampullary Adenocarcinoma", "Gallbladder Cancer", "Extrahepatic Bile Duct Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New Mexico Cancer Research Alliance", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2007-08", "completion_date": "2017-03-15", "has_results": true, "last_update_posted_date": "2018-06-29", "last_synced_at": "2026-09-21T15:46:03.053Z", "location_count": 2, "location_summary": "San Francisco, California • Albuquerque, New Mexico", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00832637" }, { "nct_id": "NCT02951052", "title": "Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "Cabotegravir (CAB) tablet", "type": "DRUG" }, { "name": "Rilpivirine (RPV) tablet", "type": "DRUG" }, { "name": "Cabotegravir - Injectable Suspension (CAB LA)", "type": "DRUG" }, { "name": "Rilpivirine - Injectable Suspension (RPV LA)", "type": "DRUG" }, { "name": "2 NRTIs plus an INI, NNRTI, or PI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 618, "start_date": "2016-10-28", "completion_date": "2029-12-31", "has_results": true, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-09-21T15:46:03.053Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02951052" }, { "nct_id": "NCT02120352", "title": "A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "CAB Oral Tablets", "type": "DRUG" }, { "name": "CAB LA", "type": "DRUG" }, { "name": "ABC/3TC Oral tablets", "type": "DRUG" }, { "name": "RPV Oral Tablets", "type": "DRUG" }, { "name": "HAART", "type": "OTHER" }, { "name": "RPV", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 309, "start_date": "2014-04-28", "completion_date": "2023-04-20", "has_results": true, "last_update_posted_date": "2024-06-12", "last_synced_at": "2026-09-21T15:46:03.053Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02120352" }, { "nct_id": "NCT07363395", "title": "Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuropathic Pain" ], "interventions": [ { "name": "ASCT-83", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alcamena Stem Cell Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 72, "start_date": "2026-01-06", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-09-21T15:46:03.053Z", "location_count": 1, "location_summary": "Saint Paul, Minnesota", "locations": [ { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07363395" }, { "nct_id": "NCT02677623", "title": "Evaluation of Ureteral Patency in the Post-indigo Carmine Era", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ureteral Patency" ], "interventions": [ { "name": "Pyridium", "type": "DRUG" }, { "name": "Sodium Fluorescein", "type": "DRUG" }, { "name": "Mannitol", "type": "DRUG" }, { "name": "Normal Saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 140, "start_date": "2015-03", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2019-05-30", "last_synced_at": "2026-09-21T15:46:03.053Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02677623" } ] }